Skip to main content
BioPlus Co., Ltd logo

BioPlus Co., Ltd — Investor Relations & Filings

Ticker · 099430 ISIN · KR7099430001 KO Manufacturing
Open in API
Filings indexed 227 across all filing types
Latest filing 2021-10-29 Major Shareholding Noti…
Country KR South Korea
Listing KO 099430

About BioPlus Co., Ltd

https://ubioplus.com/

BioPlus Co., Ltd. is a company that researches, develops, and manufactures biomaterials, with a primary focus on hyaluronic acid (HA) applications. The company's core competency is its proprietary MDM® Technology, which is used to create a diverse product portfolio for the beauty and healthcare industries. Key products include a range of dermal and body fillers, skin boosters, anti-adhesion agents, biomaterial breast implants, and artificial cartilage. The company aims to provide bio-therapy solutions by addressing fundamental cellular-level issues through its advanced technologies.

Recent filings

Filing Released Lang Actions
타법인주식및출자증권취득결정(자율공시)
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (Bioplus) announcing the acquisition of shares in another company (NobleGen). This type of disclosure, which details the acquisition of equity in another entity for strategic purposes, falls under the category of M&A activity or corporate investment announcements. Given the provided categories, 'TAR' (M&A Activity) is the most appropriate classification for announcements regarding mergers, acquisitions, or strategic equity investments.
2021-10-29 Korean
[기재정정]타법인주식및출자증권취득결정(자율공시)
M&A Activity Classification · 100% confidence The document is a regulatory filing from a Korean company (BioPlus) regarding the acquisition of shares in another company (NobleGen). It details the investment amount, purpose (strategic partnership for antiviral drug development), and board approval. This type of disclosure regarding corporate investment and M&A-related activity is classified under M&A Activity (TAR) as it pertains to the acquisition of equity in another entity.
2021-10-29 Korean
[첨부추가]타법인주식및출자증권취득결정(자율공시)
M&A Activity Classification · 100% confidence The document is a regulatory filing from a Korean company (Bioplus) announcing the acquisition of shares in another company (Ubiprotein). This type of disclosure, which details the acquisition of equity in another entity, falls under M&A activity (mergers and acquisitions) as it describes a strategic investment and business expansion. In the provided taxonomy, 'TAR' (M&A Activity) is the most appropriate category for announcements regarding corporate acquisitions and takeovers.
2021-10-21 Korean
[기재정정]전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Bioplus regarding the exercise of conversion rights (convertible bonds into shares). It details the number of shares issued, the conversion price, and the remaining balance of convertible bonds. This type of disclosure regarding capital structure changes and share issuance falls under the category of share issues or capital changes.
2021-10-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) used when an insider (director or major shareholder) reports changes in their shareholdings, such as exercising stock options. This falls under the category of 'Director's Dealing' (DIRS) as it details personal share transactions by a company executive.
2021-10-20 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). This type of filing is specifically used to report insider transactions, such as stock option exercises or changes in share ownership by company directors and executives. According to the provided definitions, this falls under 'Director's Dealing' (DIRS).
2021-10-20 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.